{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:30:27Z","timestamp":1787031027943,"version":"build-2736575974"},"reference-count":69,"publisher":"American Society of Consultant Pharmacists","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2014,3,1]]},"DOI":"10.4140\/tcp.n.2014.169","type":"journal-article","created":{"date-parts":[[2014,3,3]],"date-time":"2014-03-03T21:04:55Z","timestamp":1393880695000},"page":"169-178","source":"Crossref","is-referenced-by-count":4,"title":["Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Focus in the Geriatric Population"],"prefix":"10.4140","volume":"29","author":[{"given":"Luigi","family":"Brunetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jentora","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2625","published-online":{"date-parts":[[2014,3,3]]},"reference":[{"issue":"8","key":"1","article-title":"ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"2011","author":"LS Wann","year":"2011","journal-title":"Heart Rhythm"},{"key":"2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ahj.2010.11.002","article-title":"Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients","volume":"161","author":"MB Sellers","year":"2011","journal-title":"Am Heart J"},{"key":"3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/ageing\/afr097","article-title":"Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review","volume":"40","author":"D Pugh","year":"2011","journal-title":"Age Ageing"},{"key":"4","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/archinte.163.13.1580","article-title":"Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians\u2019 fears often unfounded","volume":"163","author":"M Man-Son-Hing","year":"2003","journal-title":"Arch Intern Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1161\/STROKEAHA.108.526988","article-title":"Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators","volume":"40","author":"C van Walraven","year":"2009","journal-title":"Stroke"},{"key":"6","first-page":"165","article-title":"Use of anticoagulants in elderly patients: practical recommendations","volume":"4","author":"H Robert-Ebadi","year":"2009","journal-title":"Clin Interv Aging"},{"key":"7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/ageing\/afr128","article-title":"Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation","volume":"40","author":"N Riva","year":"2011","journal-title":"Age Ageing"},{"key":"8","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJMp1302834","article-title":"Dabigatran and postmarketing reports of bleeding","volume":"368","author":"MR Southworth","year":"2013","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation: a prospective nationwide cohort study","volume":"61","author":"TB Larsen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.annemergmed.2013.02.008","article-title":"Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin","volume":"61","author":"R Berger","year":"2013","journal-title":"Ann Emerg Med"},{"key":"11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002758","article-title":"Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study","volume":"3","author":"R Sorensen","year":"2013","journal-title":"BMJ Open"},{"key":"12","unstructured":"PradaxaR [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; March 2011."},{"key":"13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","article-title":"Dabigatran etexilate: a new oral thrombin inhibitor","volume":"123","author":"GJ Hankey","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"14","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"J Stangier","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"15","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/eurheartj\/ehr052","article-title":"Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism","volume":"32","author":"J Steffel","year":"2011","journal-title":"Eur Heart J"},{"key":"16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/978-3-642-00663-0_13","article-title":"Drug-induced liver injury in humans: the case of ximelgatran","volume":"196","author":"M Keisu","year":"2010","journal-title":"Handb Exp Pharmacol"},{"key":"17","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1345\/aph.1R720","article-title":"Dabigatran: is there a role for coagulation assays in guiding therapy?","volume":"47","author":"L Brunetti","year":"2013","journal-title":"Ann Pharmacother"},{"key":"18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0031-1300946","article-title":"The oral thrombin inhibitor dabigatran: strengths and weaknesses","volume":"38","author":"S Schulman","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"19","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jacc.2011.01.010","article-title":"2011 ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"57","author":"LS Wann","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Akl EA, Crowther M et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:7S-47S.","DOI":"10.1378\/chest.1412S3"},{"key":"21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"22","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Dabigatran etexilate. Advisory committee briefing document, August 27, 2010. http:\/\/www.Fda.Gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/cardiovascularandrenaldrugsadvisorycommittee\/ucm226009.pdf. Accessed November 1, 2012. <a target=\"_blank\" href='http:\/\/www.Fda.Gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/cardiovascularandrenaldrugsadvisorycommittee\/ucm226009.pdf'>http:\/\/www.Fda.Gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/cardiovascularandrenaldrugsadvisorycommittee\/ucm226009.pdf<\/a>"},{"key":"23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"BF Gage","year":"2006","journal-title":"Am Heart J"},{"key":"24","doi-asserted-by":"crossref","unstructured":"You JJ, Singer DE, Howard PA et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e531S-75S.","DOI":"10.1378\/chest.141.4.1129b"},{"key":"25","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2011.09.030","article-title":"Impact of CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation","volume":"125","author":"PK Mason","year":"2012","journal-title":"Am J Med"},{"key":"26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","article-title":"Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin","volume":"105","author":"RJ Beyth","year":"1998","journal-title":"Am J Med"},{"key":"27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"R Pisters","year":"2010","journal-title":"Chest"},{"key":"28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study","volume":"58","author":"MC Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1378\/chest.12-0608","article-title":"Predictive value of the HASBLED and ATRIA bleeding scores for the risk of serious bleeding in a \u201creal-world\u201d population with atrial fibrillation receiving anticoagulant therapy","volume":"143","author":"V Roldan","year":"2013","journal-title":"Chest"},{"key":"30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","article-title":"Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study","volume":"60","author":"S Apostolakis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ackd.2010.06.002","article-title":"Systemic anticoagulation considerations in chronic kidney disease","volume":"17","author":"WE Dager","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"32","unstructured":"PradaxaR European Medicines Agency. Accessed at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf. <a target=\"_blank\" href='http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf'>http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf<\/a>"},{"key":"33","unstructured":"PradaxaR Canadian prescribing information. Accessed at http:\/\/www. boehringer-ingelheim.ca\/en\/Home\/Human_Health\/Our_Products\/Product_Monographs\/Pradax-pm.pdf. <a target=\"_blank\" href='http:\/\/www. boehringer-ingelheim.ca\/en\/Home\/Human_Health\/Our_Products\/Product_Monographs\/Pradax-pm.pdf'>http:\/\/www. boehringer-ingelheim.ca\/en\/Home\/Human_Health\/Our_Products\/Product_Monographs\/Pradax-pm.pdf<\/a>"},{"key":"34","unstructured":"ISMP Medication Safety Alert. 2012;17."},{"key":"35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7326\/0003-4819-157-1-201207030-00467","article-title":"Dabigatran: uncharted waters and potential harms","volume":"157","author":"RP Radecki","year":"2012","journal-title":"Ann Intern Med"},{"key":"36","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2011.314","article-title":"The use of dabigatran in elderly patients","volume":"171","author":"M Legrand","year":"2011","journal-title":"Arch Intern Med"},{"key":"37","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc1112874","article-title":"Bleeding risk with dabigatran in the frail elderly","volume":"366","author":"P Harper","year":"2012","journal-title":"N Engl J Med"},{"key":"38","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/phar.1282","article-title":"Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on Aging: Impact on Renal Drug Dosing","volume":"33","author":"TC Dowling","year":"2013","journal-title":"Pharmacotherapy"},{"key":"39","doi-asserted-by":"crossref","DOI":"10.1177\/0091270011415527","article-title":"Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment","volume":"52","author":"S Hariharan","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"40","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1177\/0091270011417716","article-title":"Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation","volume":"52","author":"T Lehr","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"AA Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"J Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"43","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"JW Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"44","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","article-title":"Anticoagulant options\u2014why the FDA approved a higher but not a lower dose of dabigatran","volume":"364","author":"BN Beasley","year":"2011","journal-title":"N Engl J Med"},{"key":"45","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-139-11-200312020-00007","article-title":"Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis","volume":"139","author":"LA Linkins","year":"2003","journal-title":"Ann Intern Med"},{"key":"46","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11239-011-0561-1","article-title":"Drug and dietary interactions of warfarin and novel oral anticoagulants: an update","volume":"31","author":"E Nutescu","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"47","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04453.x","article-title":"Oral bioavailability of dabigatran etexilate (PradaxaR) after co-medication with verapamil in healthy subjects","volume":"75","author":"S Hartter","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"48","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/imj.12170","article-title":"Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital","volume":"43","author":"P Chin","year":"2013","journal-title":"Intern Med J"},{"key":"49","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1Q747","article-title":"Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment","volume":"46","author":"MK Wychowski","year":"2012","journal-title":"Ann Pharmacother"},{"key":"50","doi-asserted-by":"crossref","DOI":"10.1002\/j.1875-9114.2012.01036.x","article-title":"Hemopericardium in a patient treated with dabigatran etexilate","volume":"32","author":"CA Barton","year":"2012","journal-title":"Pharmacotherapy"},{"key":"51","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1Q705","article-title":"Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients","volume":"46","author":"J Bene","year":"2012","journal-title":"Ann Pharmacother"},{"key":"52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2013.02.361","article-title":"Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose","volume":"62","author":"BC Chen","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"53","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/0897190012465955","article-title":"Treatment of dabigatranassociated bleeding: case report and review of the literature","volume":"26","author":"LM Harinstein","year":"2013","journal-title":"J Pharm Pract"},{"key":"54","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1160\/TH12-03-0149","article-title":"Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation","volume":"108","author":"A Lillo-Le Louet","year":"2012","journal-title":"Thromb Haemost"},{"key":"55","unstructured":"Bleeding with dabigatran (Pradaxa). Med Lett Drugs Ther 2011;53:98."},{"key":"56","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2146\/ajhp120055","article-title":"Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma","volume":"69","author":"LE Dumkow","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"57","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","article-title":"Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration","volume":"24","author":"NR Hartnell","year":"2004","journal-title":"Pharmacotherapy"},{"key":"58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/eurheartj\/ehs408","article-title":"Acute management of bleeding in patients on novel oral anticoagulants","volume":"34","author":"DM Siegal","year":"2013","journal-title":"Eur Heart J"},{"key":"59","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"F Schiele","year":"2013","journal-title":"Blood"},{"key":"60","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"H Heidbuchel","year":"2013","journal-title":"Europace"},{"key":"61","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1161\/CIRCULATIONAHA.112.123224","article-title":"Periprocedural management and approach to bleeding in patients taking dabigatran","volume":"126","author":"JI Weitz","year":"2012","journal-title":"Circulation"},{"key":"62","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1160\/TH11-05-0358","article-title":"Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA)","volume":"106","author":"V Pengo","year":"2011","journal-title":"Thromb Haemost"},{"key":"63","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"J van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"64","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.ajkd.2012.08.047","article-title":"Removal of dabigatran by hemodialysis","volume":"61","author":"DN Chang","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"65","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1161\/STR.0b013e3181ec611b","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"41","author":"LB Morgenstern","year":"2010","journal-title":"Stroke"},{"key":"66","doi-asserted-by":"crossref","DOI":"10.1097\/CCM.0b013e31827caaa3","article-title":"Reversing dabigatran in lifethreatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity","volume":"41","author":"WE Dager","year":"2013","journal-title":"Crit Care Med"},{"key":"67","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.amjopharm.2012.02.004","article-title":"Clinical challenges in a patient with dabigatran-induced fatal hemorrhage","volume":"10","author":"EL Cano","year":"2012","journal-title":"Am J Geriatr Pharmacother"},{"issue":"14","key":"68","first-page":"1385","article-title":"focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation\u2014developed with the special contribution of the European Heart Rhythm Association","volume":"2012","author":"AJ Camm","year":"2012","journal-title":"Europace"},{"key":"69","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1345\/aph.1R057","article-title":"Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation","volume":"46","author":"DR Mack","year":"2012","journal-title":"Ann Pharmacother"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T23:54:08Z","timestamp":1565222048000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2014\/00000029\/00000003\/art00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3,1]]}},"alternative-id":["A85J34326M8W8366"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2014.169","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3,1]]}}}